ATE259658T1 - Anästhetische zubereitung enthaltend einen nmda- antagonisten und einen alpha-2 adrenergen agonisten - Google Patents

Anästhetische zubereitung enthaltend einen nmda- antagonisten und einen alpha-2 adrenergen agonisten

Info

Publication number
ATE259658T1
ATE259658T1 AT00940519T AT00940519T ATE259658T1 AT E259658 T1 ATE259658 T1 AT E259658T1 AT 00940519 T AT00940519 T AT 00940519T AT 00940519 T AT00940519 T AT 00940519T AT E259658 T1 ATE259658 T1 AT E259658T1
Authority
AT
Austria
Prior art keywords
alpha
adrenergic agonist
nmda antagonist
anesthetical
preparation containing
Prior art date
Application number
AT00940519T
Other languages
English (en)
Inventor
Nicholas Franks
Mervyn Maze
Original Assignee
Protexeon Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10855216&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE259658(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Protexeon Ltd filed Critical Protexeon Ltd
Application granted granted Critical
Publication of ATE259658T1 publication Critical patent/ATE259658T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Anesthesiology (AREA)
  • Inorganic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AT00940519T 1999-06-11 2000-06-09 Anästhetische zubereitung enthaltend einen nmda- antagonisten und einen alpha-2 adrenergen agonisten ATE259658T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9913677.2A GB9913677D0 (en) 1999-06-11 1999-06-11 Formulation
PCT/GB2000/002271 WO2000076545A1 (en) 1999-06-11 2000-06-09 Anaesthetic formulation comprising an nmda-antagonist and an alpha-2 adrenergic agonist

Publications (1)

Publication Number Publication Date
ATE259658T1 true ATE259658T1 (de) 2004-03-15

Family

ID=10855216

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00940519T ATE259658T1 (de) 1999-06-11 2000-06-09 Anästhetische zubereitung enthaltend einen nmda- antagonisten und einen alpha-2 adrenergen agonisten

Country Status (14)

Country Link
US (1) US6562855B1 (de)
EP (1) EP1187635B1 (de)
JP (1) JP2003529541A (de)
AT (1) ATE259658T1 (de)
AU (1) AU778671B2 (de)
CA (1) CA2376916C (de)
DE (1) DE60008374T2 (de)
DK (1) DK1187635T3 (de)
ES (1) ES2215678T3 (de)
GB (2) GB9913677D0 (de)
PT (1) PT1187635E (de)
RU (1) RU2244558C2 (de)
WO (1) WO2000076545A1 (de)
ZA (1) ZA200110116B (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2812545B1 (fr) * 2000-08-03 2003-03-28 Air Liquide Sante Int Aerosol medicamenteux inhalable dans le traitement ou la prevention de la douceur
GB0209998D0 (en) * 2002-05-01 2002-06-12 Protexeon Ltd Use
CN1668315A (zh) 2002-06-12 2005-09-14 梅瑟·格里斯海姆有限公司 使用含氙气体进行脑保护
EP1521598A1 (de) * 2002-07-05 2005-04-13 Air Liquide Deutschland GmbH Xenon enthaltendes adjuvans
AU2003288214A1 (en) * 2002-12-06 2004-06-30 Michael Georgieff Nasal pharmaceutical preparation containing an active lipophilic liquid or gaseous ingredient
WO2005039600A2 (en) * 2003-10-21 2005-05-06 Aga Ab Use of xenon for the prevention of programmed cell death
US7795263B2 (en) * 2008-07-08 2010-09-14 Wildlife Laboratories, Inc. Pharmaceutical combination for and method of anesthetizing and immobilizing non-domesticated mammals
US20100022574A1 (en) * 2008-07-28 2010-01-28 EndogenX, Inc. Methods to Treat Pain Using an Alpha-2 Adrenergic Agonist and an Endothelin Antagonist
US20100203165A1 (en) * 2008-08-01 2010-08-12 Gerald Horn Compositions and methods for treatment of disorders or conditions of the eye
US20110244058A1 (en) * 2008-08-01 2011-10-06 Gerald Horn Compositions and methods for treatment of pulmonary diseases and conditions
ES2518418T3 (es) 2008-08-01 2014-11-05 Eye Therapies Llc Composiciones de vasoconstricción y métodos de uso
US12246013B2 (en) 2008-08-01 2025-03-11 Eye Therapies Llc Vasoconstriction compositions and methods of use
US8952011B2 (en) 2008-08-01 2015-02-10 Eye Therapies Llc Compositions and methods for the treatment of nasal conditions
EP3305281A1 (de) * 2009-05-15 2018-04-11 Recro Pharma, Inc. Sublinguale dexmedetomidinzusammensetzungen und verfahren zur verwendung davon
US8987270B2 (en) 2009-07-27 2015-03-24 Eye Therapies Llc Formulations of selective alpha-2 agonists and methods of use thereof
WO2011075621A1 (en) * 2009-12-17 2011-06-23 Alpha Synergy Development, Inc. Compositions and methods for ophthalmic delivery of nasal decongestants
EP2521544A4 (de) * 2010-01-08 2013-08-21 Recro Pharma Inc Topische transdermale dexmedetomidinzusammensetzungen und verfahren zu ihrer verwendung
CA2796280A1 (en) * 2010-04-15 2011-10-20 The Royal Institution For The Advancement Of Learning / Mcgill Universit Y Topical treatments for pain
US8445526B2 (en) 2011-02-03 2013-05-21 Glaucoma & Nasal Therapies Llc Compositions and methods for treatment of glaucoma
US20130096170A1 (en) 2011-10-14 2013-04-18 Hospira, Inc. Methods of treating pediatric patients using dexmedetomidine
CA2858721C (en) 2011-12-11 2021-03-16 Recro Pharma, Inc. Intranasal dexmedetomidine compositions and methods of use thereof
CN103565745A (zh) 2012-08-10 2014-02-12 德克萨斯州大学系统董事会 用于治疗中风的神经保护性脂质体组合物和方法
EP4082552B1 (de) 2013-03-15 2026-05-06 The Board of Regents of the University of Texas System Edelgasreiche flüssigkeiten sowie verfahren zu deren herstellung und verwendung
US8999938B2 (en) 2013-06-21 2015-04-07 Gnt Llc Ophthalmic lipophilic drug delivery vehicle formulations
RU2018105761A (ru) 2013-10-07 2019-02-26 ТЕЙКОКУ ФАРМА ЮЭсЭй, ИНК. Устройства для трансдермальной доставки дексмедетомидина и способы их применения
TWI709417B (zh) 2013-10-07 2020-11-11 美商帝國製藥美國股份有限公司 使用右美托咪啶經皮組成物用於治療注意力不足過動症、焦慮及失眠的方法及組成物
RU2648449C2 (ru) 2013-10-07 2018-03-26 ТЕЙКОКУ ФАРМА ЮЭсЭй, ИНК. Способы и композиции для трансдермальной доставки неседативного количества дексмедетомидина
RU2557882C1 (ru) * 2014-07-08 2015-07-27 Государственное бюджетное образовательное учреждение высшего профессионального образования "Астраханская государственная медицинская академия" Министерства здравоохранения Российской Федерации (ГБОУ ВПО АГМА Минздрава России) Способ проведения премедикации при плановом хирургическом лечении
WO2017139382A1 (en) * 2016-02-08 2017-08-17 The Texas A&M University System Combination of adjuvant drugs esketamine and brimonidine for medical treatments
KR20210113439A (ko) 2016-10-31 2021-09-15 테이코쿠 팔마 유에스에이, 인코포레이티드 덱스메데토미딘 경피 전달 장치를 이용한 통증을 관리하는 방법
US12280096B2 (en) 2021-07-12 2025-04-22 Penland Foundation Treatments of cancer using nitrous oxide and botulinum toxin
US12599625B2 (en) 2021-05-13 2026-04-14 Penland Foundation Treatment of ARDS and other conditions caused by acutely elevated cytokine levels and post ARDS chronic cytokine production using inhaled anesthetics

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4859685A (en) * 1986-08-13 1989-08-22 Boc, Inc. Anesthetic composition and method of using the same
US5605911A (en) * 1995-01-31 1997-02-25 Washington University Use of alpha-2 adrenergic drugs to prevent adverse effects of NMDA receptor hypofunction (NRH)
JP2000500020A (ja) 1995-11-13 2000-01-11 コミサリア・ア・レネルジー・アトミーク 正十二面体様アデノウイルス・タンパク質複合体、それを含む組成物、及びその使用方法
DE19709704C2 (de) 1997-03-10 1999-11-04 Michael Georgieff Verwendung einer flüssigen Präparation von Xenon zur intravenösen Verabreichung bei Einleitung und/oder Aufrechterhaltung der Anaesthesie
FR2787713A1 (fr) * 1998-12-23 2000-06-30 Johan Huysman Composition en tant que medicament et utilisation d'une telle composition pour l'obtention d'un medicament destine a l'anesthesie, notamment medicament analgesique
DE19910986C2 (de) 1999-03-11 2001-06-07 Aga Ab Verwendung von Xenon bei der Behandlung von Neurointoxikationen
GB9917822D0 (en) * 1999-07-29 1999-09-29 Imperial College Nmda antagonist

Also Published As

Publication number Publication date
WO2000076545A1 (en) 2000-12-21
PT1187635E (pt) 2004-07-30
ZA200110116B (en) 2003-07-23
DK1187635T3 (da) 2004-06-21
AU778671B2 (en) 2004-12-16
DE60008374T2 (de) 2004-12-09
GB2352633A (en) 2001-02-07
US6562855B1 (en) 2003-05-13
EP1187635B1 (de) 2004-02-18
GB2352633B (en) 2002-04-17
DE60008374D1 (de) 2004-03-25
CA2376916A1 (en) 2000-12-21
RU2244558C2 (ru) 2005-01-20
JP2003529541A (ja) 2003-10-07
ES2215678T3 (es) 2004-10-16
GB9913677D0 (en) 1999-08-11
AU5544400A (en) 2001-01-02
CA2376916C (en) 2010-09-21
EP1187635A1 (de) 2002-03-20
GB0014165D0 (en) 2000-08-02

Similar Documents

Publication Publication Date Title
DE60008374D1 (de) Anästhetische zubereitung enthaltend einen nmda-antagonisten und einen alpha-2 adrenergen agonisten
MY129356A (en) Electrospun pharmaceutical compositions
EP1762236A3 (de) Formulierungen von alpha-adrenergen Rezeptor-Antagonisten und ihre Anwendungen
CY1108532T1 (el) Ενωσεις και συνθεσεις για την παροχη δραστικων παραγοντων
NO20024309D0 (no) Intradermal penetreringsmidler for topikal lokal anestetisk administrering
EA200401009A1 (ru) Предварительно желатинированный крахмал в композиции с контролируемым высвобождением
DK1036059T3 (da) Adamantanderivater
GB2365772A (en) Factor
DE60111265D1 (de) Pharmazeutische zusammensetzungen mit nmda-rezeptor-agonist
HK1045113A1 (zh) 給予固定的曲馬朵和雙氯酚酸組合的口服給藥形式
SE0102843L (sv) Stabiliserad oral farmaceutisk komposition innehållande jodid och jodat och metod
BG105257A (en) New oral formulation for 5-ht4 agonists or antagonists
ATE287264T1 (de) Oral anzuwendende buprenorphinhaltige arzneimittel
DE60102590D1 (de) Darreichungsformen zur behandlung von oralen mykosen
MY141012A (en) Combination comprising an at1-receptor antagonist and an insulin secretion enhancer or an insulin sensitiser
ATE258045T1 (de) Verfahren zu herstellung von pulverförmigen solubilisationshilfsstoffen für feste pharmazeutische darreichungsformen
ATE254851T1 (de) Iod-herstellungszusammensetzung
NO20010537L (no) Farmasøytiske preparater omfattende ibuprofen og domperidon
DE60111503D1 (de) Pharmazeutische zusammensetzungen enthaltend terbinafin
MY130445A (en) Novel formulations of alpha-2, 4-disulfophenyl-n-tert-butylnitrone
DE50114127D1 (de) Torasemid enthaltende lagerstabile pharmazeutische zubereitungen
CY1108502T1 (el) Ελεγχομενης-αποδεσμευσης συνθεσεις οι οποιες περιεχουν οπιοειδη αγωνιστη και ανταγωνιστη
BR9909529A (pt) Maleato de paroxetina
UA89408C2 (ru) Твердая фармацевтическая композиция пролонгированного высвобождения 1-(2,3,4-триметоксибензил)пиперазина и способ ее получения
AU2002235767A1 (en) Novel pharmaceutical compositions based on anticholinergic agents and dopamine agonists

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1187635

Country of ref document: EP